Open AccessPrimary Neuroendocrine Carcinoma of the Breast Metastatic to the Bones, Which Chemotherapy?
Author(s) -
Soe Aye M.,
Joseph Gardith,
Guevara Elizabeth,
Xiao Philip
Publication year - 2017
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/tbj.12800
Subject(s) - medicine , chromogranin a , neuroendocrine carcinoma , breast carcinoma , breast cancer , metastasis , immunohistochemistry , oncology , chemotherapy , disease , pathology , carcinoma , metastatic breast cancer , sex organ , cancer , biology , genetics
The primary neuroendocrine carcinoma ( NEC ) of the breast is defined as immunohistochemical expression of neuroendocrine markers (chromogranin and synoptophysin) in more than 50% of the neoplastic cells according to World Health Organization ( WHO ) classification of tumors in 2003 ( Tumours of the Breast and Female Genital Organs , 2003, Lyon: IARC Press). It accounts for less than 5% of all cancers arising from the breast ( Tumours of the Breast and Female Genital Organs , 2003, Lyon, France: IARC Press). However, based on the study conducted by Wang et al., the primary NEC of breast comprises less than 0.1% of all mammary carcinomas ( Frankf Z Pathol , 73 , 1963, 24). Because of the rarity of the disease and absence of the prospective trials, there is no standard treatment for primary NEC of the breast. Herein, we report the case of a middle age woman with primary NEC with bone metastasis.